| Safety, Growth, and Development After Dapagliflozin or Saxagliptin in Children With Type 2 Diabetes (T2NOW Follow-Up).J Clin Endocrinol Metab | PMID 39446459PMC12086385 | 2025-May-19 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Long-term safety and efficacy of Oleogel-S10 (birch bark extract) in epidermolysis bullosa: 24-month results from the phase III EASE study.Br J Dermatol | PMID 39821055无 PMCID | 2025-May-19 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Evaluating the concordance between BICLA and SRI4 in patients with systemic lupus erythematosus from the placebo arms of the EXPLORER and ATHOS trials.Lupus Sci Med | PMID 40389370PMC12090859 | 2025-May-19 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Diverse Lenabasum pathway activation in dermatomyositis patients' blood.Sci Rep | PMID 40383862PMC12086228 | 2025-May-18 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trial.Lancet | PMID 40347969无 PMCID | 2025-May-17 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| SLE-DAS enables an accurate definition of severe lupus disease activity: derivation and validation in a post hoc study of anifrolumab phase II and III studies.Lupus Sci Med | PMID 40379439PMC12086896 | 2025-May-16 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A Randomized, Double-Blind, Placebo-Controlled, Multicentered Study to Evaluate the Efficacy and Safety of MEI005 in Reducing Submental Fat in Chinese Adults.Aesthet Surg J | PMID 40037621PMC12080881 | 2025-May-15 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Tolebrutinib versus Teriflunomide in Relapsing Multiple Sclerosis.N Engl J Med | PMID 40202623无 PMCID | 2025-May-15 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis.N Engl J Med | PMID 40202696无 PMCID | 2025-May-15 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up from the randomized phase III KEYNOTE-048 study.Eur J Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40262400无 PMCID | 2025-May-15 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Predictive Effect of IGFBP-3 on Low-Dose Tamoxifen Efficacy in Noninvasive Breast Cancer in the Phase III Tam-01 Trial.Clin Cancer Res | PMID 40293268无 PMCID | 2025-May-15 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Cemiplimab monotherapy as first-line treatment of patients with brain metastases from advanced non-small cell lung cancer with programmed cell death-ligand 1 ≥50.Cancer | PMID 40323717PMC12051739 | 2025-May-15 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 已完成 |
| Second-Line Antiretroviral Therapy for Children Living with HIV in Africa.N Engl J Med | PMID 40367375PMC7617794 | 2025-May-15 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Tuberculosis disease characteristics associated with mortality, severe morbidity and unsuccessful treatment in people living with HIV treated for tuberculosis - a secondary analysis of the ANRS 12300 Reflate TB2 trial.BMC Infect Dis疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40361016PMC12077038 | 2025-May-14 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Interim PET after 4 cycles predicts outcome in histomolecularly confirmed primary mediastinal B-cell lymphoma.Blood Adv | PMID 40030008PMC12088757 | 2025-May-13 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 已完成 |
| Adjuvant PD-1 Blockade With Camrelizumab for Nasopharyngeal Carcinoma: The DIPPER Randomized Clinical Trial.JAMA疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40079940PMC11907361 | 2025-May-13 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Atezolizumab in High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Randomized Clinical Trial.JAMA疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40079944PMC11907359 | 2025-May-13 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Inhaled Sedation in Acute Respiratory Distress Syndrome: The SESAR Randomized Clinical Trial.JAMA | PMID 40098564PMC11920880 | 2025-May-13 | 0.98 | 未发现恶性肿瘤人群证据。 | 已完成 |
| Subcutaneous Ocrelizumab in Patients With Multiple Sclerosis: Results of the Phase 3 OCARINA II Study.Neurology | PMID 40245351PMC12006663 | 2025-May-13 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Neoadjuvant PARP inhibitor scheduling in BRCA1 and BRCA2 related breast cancer: PARTNER, a randomized phase II/III trial.Nat Commun | PMID 40360463PMC12075821 | 2025-May-13 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Effectiveness of a community-based rehabilitation programme following hip fracture: results from the Fracture in the Elderly Multidisciplinary Rehabilitation phase III (FEMuR III) randomised controlled trial.BMJ Open | PMID 40355296PMC12083281 | 2025-May-12 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Probiotic reduces vaginal HPV abundance, improves immunity and quality of life in HPV-positive women: a randomised, placebo-controlled and double-blind study.Benef Microbes | PMID 40360161无 PMCID | 2025-May-12 | 0.85 | The study is a randomized, Phase III oncology-related trial, but it does not report the required survival or progression outcomes. It focuses on HPV viral load, immune markers, and quality of life, which are not definitive efficacy outcomes for this adjudication. | 待处理 |
| Wearable Devices in Remote Cardiac Rehabilitation With and Without Weekly Online Coaching for Patients With Coronary Artery Disease: Randomized Controlled Trial.JMIR Mhealth Uhealth | PMID 40395066PMC12088619 | 2025-May-12 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Upadacitinib as monotherapy in patients with rheumatoid arthritis and prior inadequate response to methotrexate: results at 260 weeks from the SELECT-MONOTHERAPY randomised study.RMD Open | PMID 40350200PMC12067782 | 2025-May-11 | 0.45 | The record is a randomized, phase III trial of a drug (upadacitinib) in a human, but it is for rheumatoid arthritis, not a malignant neoplasm. Therefore, it fails the core oncology criterion. | 待处理 |
| Pertuzumab Retreatment for Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced/Metastatic Breast Cancer (PRECIOUS Study): Final Overall Survival Analysis.J Clin Oncol | PMID 39854662PMC12058362 | 2025-May-10 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Pembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-921 Trial.J Clin Oncol | PMID 40043230PMC12058370 | 2025-May-10 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| A double-blind, randomised phase III clinical trial to evaluate safety, immunogenicity, non-inferiority & lot to lot consistency of single component oral cholera vaccine BBV131 (Hillchol®) in comparison to Shanchol™.Vaccine | PMID 40174256无 PMCID | 2025-May-10 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of topical delgocitinib cream versus oral alitretinoin capsules in adults with severe chronic hand eczema (DELTA FORCE): a 24-week, randomised, head-to-head, phase 3 trial.Lancet | PMID 40252681无 PMCID | 2025-May-10 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Sustained growth-promoting effects of vosoritide in children with achondroplasia from an ongoing phase 3 extension study.Med | PMID 39740666无 PMCID | 2025-May-09 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Capivasertib plus fulvestrant in patients with HR-positive/HER2-negative advanced breast cancer: phase 3 CAPItello-291 study extended Chinese cohort.Nat Commun | PMID 40346047PMC12064754 | 2025-May-09 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| The effects of saffron supplementation on inflammation and hematological parameters in patients with sepsis: a randomized controlled trial.Nutr J | PMID 40346613PMC12063221 | 2025-May-09 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma.N Engl J Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39652675无 PMCID | 2025-May-08 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML.Blood | PMID 39775763PMC12105721 | 2025-May-08 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 已完成 |
| Association of bile acid diarrhea with symptoms and disease activity in Crohn's disease: post-hoc clinical trial analysis of serum 7a-hydroxy-4cholestern-3-one, C4, in patients with active Crohn's disease.J Crohns Colitis | PMID 40202488无 PMCID | 2025-May-08 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Influence of anti-Spike protein antibody levels on tocilizumab efficacy in hospitalized patients with severe COVID-19 pneumonia: a post-hoc analysis of the COVACTA trial.BMC Infect Dis已检查 3 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 multi panel km;Fig. 2:AI 判定为 other;Fig. 3:AI 判定为 other。 | PMID 40340657PMC12063319 | 2025-May-08 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Step up to triple therapy versus switch to dual bronchodilator therapy in patients with COPD on an inhaled corticosteroid/long-acting β2-agonist: post-hoc analyses of KRONOS.Respir Res | PMID 40340809PMC12063277 | 2025-May-08 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Patient-reported outcomes from DESTINY-Breast04: trastuzumab deruxtecan versus physician's choice of chemotherapy in patients with HER2-low mBC.Oncologist | PMID 40349139PMC12065936 | 2025-May-08 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| First-line treatment of anti-EGFR monoclonal antibody cetuximab β plus FOLFIRI versus FOLFIRI alone in Chinese patients with RAS/BRAF wild-type metastatic colorectal cancer: a randomized, phase 3 trial.Signal Transduct Target Ther | PMID 40328753PMC12056184 | 2025-May-07 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Psychometric evaluation of the HFDD, PROMIS SD SF 8b, and MENQOL questionnaire in women experiencing vasomotor symptoms associated with menopause.J Patient Rep Outcomes | PMID 40332718PMC12058613 | 2025-May-07 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| History of Cancer and Atrial Cardiopathy: A Secondary Analysis of the ARCADIA Clinical Trial.J Am Heart Assoc | PMID 40265582PMC12184225 | 2025-May-06 | 0.90 | The record describes a secondary analysis of baseline data from the ARCADIA trial (a Phase III RCT for stroke prevention) examining biomarkers for atrial cardiopathy in relation to cancer history. While the parent trial is oncology-eligible in principle (randomized, phase 3, human), this specific report is not an efficacy analysis for an oncology outcome. It does not report survival, progression, recurrence, death, hazard, or time-to-event outcomes for cancer. It is a cross-sectional analysis of biomarkers as risk factors. | 待处理 |
| Comprehensive Analysis of the Effects of Sacubitril/Valsartan According to Sex Among Patients With Heart Failure and Reduced Ejection Fraction in PARADIGM-HF.J Am Heart Assoc | PMID 40265590PMC12334938 | 2025-May-06 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Prognostic Significance of Nutritional Scores in Patients With Heart Failure: Insights From the PARAGON-HF Trial.J Am Heart Assoc | PMID 40265602PMC12184571 | 2025-May-06 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Comparison of Electronic Surveillance With Routine Monitoring for Patients With Lymphoma at High Risk of Relapse: Prospective Randomized Controlled Phase 3 Trial (Sentinel Lymphoma).JMIR Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 5 张 PMC Figure,均未识别为 KM 图:Figure 1.:AI 判定为 flow diagram;Figure 2.:CONSORT/入组流程图;Figure 3.:非 KM 图;Figure 4.:非 KM 图;Figure 5.:非 KM 图。 | PMID 40327037PMC12070818 | 2025-May-06 | 0.95 | The study is a randomized Phase III trial in oncology (lymphoma), but it evaluates a non-drug intervention (electronic surveillance) versus standard monitoring. The primary endpoint is the detection of significant events (relapse, progression, serious adverse events), not a formal time-to-event efficacy endpoint like OS, PFS, or DFS. Therefore, it does not meet the criteria for drug intervention and time-to-event endpoint. | 无 KM 图 |
| Efficacy of topical moxifloxacin on therapeutic laparoscopy-induced wound healing: a double-blind, randomized clinical trial.BMC Surg | PMID 40329263PMC12054187 | 2025-May-06 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| 8MW0511, a novel, long-acting granulocyte-colony stimulating factor fusion protein for the prevention of chemotherapy-induced neutropenia: final results from the phase III clinical trial.Breast Cancer Res | PMID 40329331PMC12057130 | 2025-May-06 | 0.95 | The study is a randomized Phase III trial in human oncology with a drug intervention and reports original results, but the primary efficacy endpoint (duration of severe neutropenia) is a continuous efficacy endpoint, not a time-to-event endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP) with Kaplan-Meier or HR analysis. | 待处理 |
| Better Mental Health and Fewer Depressive Symptoms Are Associated With Greater Psychological Resilience After Hip Fracture.J Gerontol A Biol Sci Med Sci | PMID 39780398PMC12066004 | 2025-May-05 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial.Lancet | PMID 40169145无 PMCID | 2025-May-03 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Oral gepotidacin for the treatment of uncomplicated urogenital gonorrhoea (EAGLE-1): a phase 3 randomised, open-label, non-inferiority, multicentre study.Lancet | PMID 40245902无 PMCID | 2025-May-03 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Radiation vs. trans-oral surgery for treatment de-escalation in HPV-related oropharyngeal cancers: Primary analysis of the ORATOR2 randomized trial.Eur J Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40121836无 PMCID | 2025-May-02 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 无 KM 图 |
| Induction chemotherapy followed by chemoradiation in locally advanced cervical cancer: Quality of life outcomes of the GCIG INTERLACE trial.Eur J Cancer | PMID 40139003无 PMCID | 2025-May-02 | 0.95 | Eligible trial characteristics but excluded because the reported endpoint is quality of life, not a time-to-event efficacy endpoint as required. | 待处理 |